GLPwatch

SELECT-LIFE: A Research Study Looking at Long-term Effects of Semaglutide in People Who Took Part in the SELECT Cardiovascular Outcomes Trial

NCT04972721 · Completed

Last updated 2026-05-28

This study is examining the long-term effects of the medication semaglutide in adults with overweight or obesity who previously participated in a related cardiovascular trial.

Status Completed The study has finished.
Type Observational
Participants 3,439 people
Who can join Ages 45+ · all sexes
Timeline Started 2023-09 · est. completion 2025-08
Where 38 sites · Algeria, Argentina, Australia, Brazil, Canada, Croatia, Denmark, Finland, Germany, Greece, India, Ireland, Italy, Japan, Latvia, Malaysia, Netherlands, Norway, South Africa, Sweden, Taiwan, Thailand, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT04972721 ↗

Description as written by the study sponsor.

Participants are being asked to participate in SELECT-LIFE study because participants take part in the SELECT trial. SELECT-LIFE study is a survey-based study that will start when the SELECT trial ends. SELECT-LIFE looks at the long-term effects of participants taking part in the SELECT trial including the trial medicine participants have been taking. When the SELECT trial ends, participants will no longer get the medicine participants got in the study, even if participants decide to take part in the SELECT-LIFE study. Participants will not get any specific treatment or medicine as part of the SELECT-LIFE study, and participants will be treated as participants normally would by their own doctor. The SELECT-LIFE study will last for up to 10 years after SELECT trial ends, and participants will be asked to fill in a questionnaire about their health every 6 months.

Treatments tested

Main thing measuredTime to all-cause death
SponsorNovo Nordisk A/S
Conditions studiedOverweight, Obesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04972721 ↗